Double-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson's disease

Movement Disorders

Volumn 25, Issue 6, 2010, Pages 738-746

  Bronzova, Juliana ^a   Sampaio, Cristina ^b   Hauser, Robert A ^c   Lang, Anthony E ^d   Rascol, Olivier ^e   Theeuwes, Ad ^a   Van De Witte, Serge V ^a   Van Scharrenburg, Guus ^a  

^a Solvay Pharmaceuticals Inc   (Netherlands)

^b INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

^d UNIVERSITY OF TORONTO   (Canada)

^e TOULOUSE UNIVERSITY HOSPITAL   (France)

Author keywords

Monotherapy; Pardoprunox; Parkinson's disease; Partial dopamine agonist; Randomized controlled clinical trial

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; PARDOPRUNOX; PLACEBO;

ABNORMAL DREAMING; ADULT; AGITATION; ANXIETY; ARTICLE; ASTHENIA; BLOOD PRESSURE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HALLUCINATION; HEADACHE; HUMAN; HYPERTENSION; ILLUSION; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MOTOR PERFORMANCE; MULTICENTER STUDY; NAUSEA; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PHASE 2 CLINICAL TRIAL; POLLAKISURIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; UNIFIED PARKINSON DISEASE RATING SCALE; VOMITING;

EID: 77951843531     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22948     Document Type: Article

References (34)

1. Nutt JG, Obeso JA, Stocchi F. Continuous dopamine-receptor stimulation in advanced Parkinson's disease. Trends Neurosci 2000;23(10 suppl):S109-S115.
2. Olanow CW, Schapira AHV, Rascol O. Continuous dopamine-receptor stimulation in early Parkinson's disease. Trends Neurosci 2000;23(10 suppl):S117-S126.
3. McCreary AC, Ronken E, van der Heyden J, et al. SLV308: a novel antiparkinsonian agent with antidepressant and anxiolytic properties. In: Ronken E, van Scharrenburg GJM, editors. Parkinson's disease (Solvay pharmaceutical conferences). USA: IOS Press; 2002. p 51-58.
4. 2-like dopamine receptor agonist terguride acts as a functional antagonist in states of high and low dopaminergic tone: evidence from preweanling rats. Psychopharmacology 2005;178:431-439.
5. Koller WC, Herbster G. Terguride, a mixed dopamine agonist-antagonist, in animal models of Parkinson's disease. Neurology 1987;37:723-727. (Pubitemid 17057960)
6. Lieberman A, Gopinathan G, Neophytides A, Pasternack P, Goldstein M. Advanced Parkinson's disease: use of partial dopamine agonist, ciladopa. Neurology 1987;37:863-865. (Pubitemid 17064686)
7. Verhagen Metman L, Sethy VH, Roberts JR, et al. Motor effects of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine (preclamol) in Parkinson's disease. Mov Disord 1994;9:577-581. (Pubitemid 24275075)
8. Ruggieri S, Stocchi F, Baronti F, et al. Antagonistic effect of terguride in Parkinson's disease. Clin Neuropharmacol 1991;14:450-456.
9. 1A receptor agonist. Synapse 2006;60:599-608.
10. Johnston L, Rose S, McCreary A, Jackson M, Hesselink M, Jenner P. Full (ropinirole) and partial (SLV308) dopamine agonists and the relationship to dyskinesia priming in MPTP-treated marmosets. Mov Disord 2005;20(S10):P16. [Poster.]
11. Daniel SE, Lees AJ. Parkinson's Disease Society Brain Bank, London: overview and research. J Neural Transm Suppl 1993;39:165-172.
12. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology 1967;17:427-442.
13. Fahn S, Elton RL, UPDRS development committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne D, Goldstein M, editors. Recent developments in Parkinson's disease. Vol.II. Florham Park, NJ: Macmillan; 1987. p 153-164.
14. National Institute for Mental Health. 028 CGI. Clinical global impressions. In:Guy W, editor. ECDEU assessment manual for psychopharmacology. Rockville, MD: US Department of Health, Education, and Welfare; 1976. p 217-222.
15. Schwab RS, England AC. Projection technique for evaluating surgery in Parkinson's disease. In: Gillingham FJ, Donaldson IML, editors. Third symposium of Parkinson's disease. Edinburgh: E & S Livingstone; 1969.
16. Johns MW. A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale. Sleep 1991;14:540-545.
17. Jenner P. Pharmacology of dopamine agonists in the treatment of Parkinson's disease. Neurology 2002;58(suppl 1):S1-S8. (Pubitemid 34163495)
18. Baronti F, Mouradian MM, Conant KE, Giuffra M, Brughitta G, Chase TN. Partial dopamine agonist therapy of levodopa-induced dyskinesias. Neurology 1992;42:1241-1243.
19. Feenstra R, Ronken E, Koopman T, et al. SLV308. Drugs Future 2001;26:128-132.
20. Olanow CW, Obeso JA, Stocchi F. Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol 2006;5:677-687. (Pubitemid 44081890)
21. Smith LA, Jackson MJ, Hansard MJ, Maratos E, Jenner P. Effect of pulsatile administration of levodopa on dyskinesia induction in drug-naïve MPTP-treated common marmosets: effect of dose, frequency of administration, and brain exposure. Mov Disord 2003;18:487-495. (Pubitemid 36656532)
22. Jenner P. Preventing and controlling dyskinesia in Parkinson's disease - a view of current knowledge and future opportunities. Mov Disord 2008;23(suppl 3):S585-S598.
23. 11C-raclopride. Mov Disord 2002;17(suppl 5):S120-S121 (P359).
24. 11C-raclopride and positron emission tomography. Ann Neurol 1992;31:184-192.
25. 1A agonist, alleviates L-DOPA-induced dyskinesia in patients with Parkinson's disease. No To Shinkei 2002;54:133-137. [Article in Japanese].
26. Bara-Jimenez W, Bibbiani F, Morris MJ, et al. Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease. Mov Disord 2005;20:932-936. (Pubitemid 41419506)
27. Carta M, Carlsson T, Kirik D, Björklund A. Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain 2007;130(Pt 7):1819-1833. (Pubitemid 47343795)
28. Schrag A. Quality of life and depression in Parkinson's disease. J Neurol Sci 2006;248(1-2):151-157. (Pubitemid 44647306)
29. Adler CH, Sethi KD, Hauser RA, et al; for the Ropinirole Study Group. Ropinirole for the treatment of early Parkinson's disease. Neurology 1997;49:393-399.
30. Rascol O, Dubois B, Castro Caldas A, Senn S, Del Signore S, Lees A;on behalf of the Parkinson REGAIN Study Group. Early piribedil monotherapy of Parkinson's disease: a planned seven-month report of the REGAIN study. Mov Disord 2006;21:2110-2115.
31. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA 2000;284:1931-1938.
32. Jankovic J, Watts RL, Martin W, Boroojerdi B; for theSP512 Rotigotine Transdermal System Clinical Study Group. Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease. Arch Neurol 2007;64:676-682.
33. Larsen JP, Tandberg E. Sleep disorders in patients with Parkinson's disease: epidemiology and management. CNS Drugs 2001;15:267-275. (Pubitemid 32337050)
34. Homann CN, Wenzel K, Suppan K, et al. Sleep attacks in patients taking dopamine agonists: review. BMJ 2002;324:1483-1487. (Pubitemid 34666614)